68
Participants
Start Date
January 13, 2010
Primary Completion Date
January 31, 2019
Study Completion Date
January 31, 2019
rAvPAL-PEG
The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
Mount Sinai School of Medicine, New York
Albany Medical Center, Albany
University of Pittsburgh Medical Center, Pittsburgh
University of Florida, Gainesville
University of Louisville, Kosair Charities Pediatric Clinical Research Unit, Louisville
Medical College of Wisconsin, Milwaukee
Ann and Robert H Lurie Children's Hospital, Chicago
Washington University Center for Applied Research Sciences, St Louis
University of Missouri, Columbia
Nebraska Medical Center, Omaha
The Children's Hospital, Aurora
University of Utah Hospital, Salt Lake City
Oregon Health and Science University, Portland
Children's Hospital Boston, Boston
Lead Sponsor
BioMarin Pharmaceutical
INDUSTRY